Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q2 2021 · 10-Q
Revenue$9.42M$9.42M+10.5% vs Q2 2020 Net Income-$17.66M-$17.66MN/M vs Q2 2020 EPS Diluted-$0.52-$0.52N/M vs Q2 2020 Operating Income-$17,483,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,673,000N/M Margins · derivedOperating margin-185.7%−112.9 pt vs Q2 2020
Net margin-187.5%−116.8 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end